First-in-class, non-opioid pain medicine (SBS-147) for acute and chronic pain
Official title: Clinical Development of SBS-147: First-in-class Oral Arylepoxamide Agonist for Pain
Funded at Sparian Biosciences, INC. · NIH-11361715 · Data updated 2026-11-12
A new non-opioid pill called SBS-147 may help adults manage acute and chronic pain with less risk of dependence or overdose.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sparian Biosciences, INC. NIH-funded |
| Lab location | 1 site (New York City, United States) |
| Project start | July 1, 2025 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $3,084,524 |
| NIH project number | 5UG3DA064392-02 |
| Project ID | NIH-11361715 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with acute or chronic pain who may benefit from non-opioid analgesia and who are able to participate in early clinical development.
✕Less likely to help
Individuals whose pain is not driven by mechanisms addressed by SBS-147 or who have contraindications to this class of drug.
What this research studies
This grant supports the development of SBS-147, an oral AEAr agonist designed to relieve various kinds of pain without the dependence risks associated with opioids. The approach focuses on early human-grade research to translate promising preclinical results into a safe, effective pain-relief option. If successful, this project could lead to a new non-opioid treatment that reduces opioid exposure for patients with acute or persistent pain.
Why it matters
Potential benefit: If successful, SBS-147 could provide strong pain relief with lower risk of dependence and overdose compared with opioids.
How similar studies have gone: Other non-opioid analgesics in development have shown promise, but SBS-147 is a first-in-class AEAr agonist with a novel mechanism.
Where this research is happening
-
Sparian Biosciences, INC.
New York City, United States Active
Researchers
- Principal investigator: Pasternak, Anna — Sparian Biosciences, INC.
- Study coordinator: Pasternak, Anna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.